Showing results (431-440 of 449) with videos related to

Sort By:
Pageof 45
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Ejhaem|February 2, 2026
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive CohortA Coste, S Godet, S Manier, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
British Journal of Haematology|May 15, 2024
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registryB Ferment, J Lambert, D Caillot, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
The EMBO Journal|May 25, 2021
Phospho-regulation, nucleotide binding and ion access control in potassium-chloride cotransportersGamma Chi, Rebecca Ebenhoch, Henry Man, et al.
Nature Communications|March 6, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myelomaC Grandclément, C Estoppey, E Dheilly, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2025
European Myeloma Network Group review and consensus statement on primary plasma cell leukemiaP Musto, M Engelhardt, N W C J van de Donk, et al.
Pageof 45